Thumbnail image of graphical abstract

The rapid development of drug resistance in microbes, the toxicity, and side effects of existing anti-infectious drugs are factors stimulating the effort directed toward a new generation of antibiotics. On page 790, Nikola Minovski, Andrej Perdih, Marjana Novic, and Tom Solmajer demonstrate how carefully validated in silico models using the recently determined structures of M. tuberculosis- DNA gyrase apoprotein and topoisomerase II-DNA-6-fluoroquinolones complexes are proficiently used for defining the drugs' binding pockets and the subsequent design of a series of novel inhibitors of DNA gyrase from the class of substituted 6-fluoroquinolones (shown on the cover).